Evan Fynes, MD
Urology · Daytona Beach, FLNPI 1790949873
Payments from drug & device makers
Across 221 payments — averaging $1464.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$245K
- Janssen Research & Development, LLC$43K
- Dendreon Pharmaceuticals LLC$32K
- Astellas Pharma US Inc$519
- Intuitive Surgical$444
- AbbVie$331
- plus $2K from 34 others
Across 1 payment — averaging $5100.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Dendreon Pharmaceuticals LLC$5K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 24 | $244,949 |
| Janssen Research & Development, LLC | 7 | $42,664 |
| Dendreon Pharmaceuticals LLC | 12 | $32,466 |
| Astellas Pharma US Inc | 32 | $519 |
| Intuitive Surgical | 7 | $444 |
| AbbVie(2 entities) | 19 | $331 |
| Pfizer | 16 | $312 |
| Johnson & Johnson | 17 | $275 |
| Novartis | 10 | $196 |
| Boston Scientific | 3 | $145 |
| Bayer | 6 | $139 |
| Merck | 7 | $131 |
| Urogpo LLC | 3 | $79 |
| Myriad Genetic Laboratories, Inc. | 3 | $74 |
| Urogen Pharma, Inc. | 4 | $69 |
| Teleflex LLC | 3 | $69 |
| Verity Pharmaceuticals Inc. | 5 | $68 |
| Coloplast | 3 | $63 |
| Cook Medical LLC | 5 | $57 |
| Sun Pharmaceutical Industries Inc. | 3 | $51 |
| Foundation Medicine, Inc. | 2 | $48 |
| Procept Biorobotics Corporation | 1 | $46 |
| Endo USA, Inc. | 2 | $43 |
| Ferring Pharmaceuticals Inc. | 2 | $42 |
| Smith+Nephew | 2 | $41 |
| Blue Earth Diagnostics | 2 | $38 |
| AstraZeneca | 2 | $37 |
| Antares Pharma, Inc. | 2 | $31 |
| Ambu Inc. | 1 | $28 |
| Alnylam Pharmaceuticals Inc. | 1 | $27 |
| Dentsply IH Inc. | 2 | $26 |
| Endo Pharmaceuticals Inc. | 1 | $19 |
| Medtronic | 1 | $16 |
| Tolmar, Inc. | 1 | $15 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $14 |
| Olympus America Inc. | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Myovant Sciences Inc. | 1 | $13 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $12 |
| SN Holdings, LLC | 5 | $0 |
How this compares
$323,623 in reported general payments places this provider in the 95th percentile of 935 urology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other urology in Daytona Beach
- Samuel LawindyDaytona Beach$268K
- Steven KesterPompano Beach$5.7M
- Harvey SamowitzHallandale Beach$3.6M
- Paul PeritoCoral Gables$3.6M
- Graham GreeneLakeland$2.5M
- Scott SellingerTallahassee$2.3M
- Fernando BiancoHialeah$2.2M
- Osvaldo PadronTampa$1.3M
- Mark Anthony GonzalgoMiami$1.1M
- Paul CrispenGainesville$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.